Antitumor activity of dual-specific T cells and influenza virus

Cancer Gene Therapy

Volumn 14, Issue 5, 2007, Pages 499-508

  Murphy, A ^a   Westwood, J A ^a   Brown, L E ^b   Teng, M W L ^a   Moeller, M ^a   Xu, Y ^a   Smyth, M J ^a,b   Hwu, P ^c   Darcy, P K ^a,b   Kershaw, M H ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROBIOTIC AGENT;

ACTIVE IMMUNIZATION; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DNA MODIFICATION; INFLUENZA VIRUS; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PERITONEAL CAVITY; PRIORITY JOURNAL; SPLEEN; T LYMPHOCYTE; TUMOR;

ANIMALS; ANTIGENS, NEOPLASM; IMMUNOTHERAPY, ADOPTIVE; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED STRAINS; ORTHOMYXOVIRIDAE; RECEPTOR, ERBB-2; T-LYMPHOCYTES;

MUS; ORTHOMYXOVIRIDAE;

EID: 34247123205     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7701034     Document Type: Article

References (33)

1. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003; 198: 569-580.
2. Marzo AL, Lake RA, Robinson BW, Scott B. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res 1999; 59: 1071-1079.
3. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233: 1318-1321.
4. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003; 3: 666-675.
5. Huang J, Khong HT, Dudley ME, El-Gamil M, Li YF, Rosenberg SA et al. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother 2005; 28: 258-267.
6. Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, Zhou J et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 2004; 173: 7125-7130.
7. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23: 2346-2357.
8. Kershaw MH, Westwood JA, Hwu P. Dual-specific T cells combine proliferation and antitumor activity. Nat Biotechnol 2002; 20: 1221-1227.
9. Marshall DR, Turner SJ, Belz GT, Wingo S, Andreansky S, Sangster MY et al. Measuring the diaspora for virus-specific CD8+ T cells. Proc Natl Acad Sci USA 2001; 98: 6313-6318.
10. Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM et al. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 2002; 100: 3155-3163.
11. Darcy PK, Haynes NM, Snook MB, Trapani JA, Cerruti L, Jane SM et al. Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL. J Immunol 2000; 164: 3705-3712.
12. Deliyannis G, Jackson DC, Ede NJ, Zeng W, Hourdakis I, Sakabetis E et al. Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus. J Virol 2002; 76: 4212-4221.
13. Doherty PC, Hou S, Tripp RA. CD8+ T-cell memory to viruses. Curr Opin Immunol 1994; 6: 545-552.
14. Marzo AL, Kinnear BF, Lake RA, Frelinger JJ, Collins EJ, Robinson BW et al. Tumor-specific CD4+ T cells have a major 'post-licensing' role in CTL mediated anti-tumor immunity. J Immunol 2000; 165: 6047-6055.
15. Stern M, Herrmann R. Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol 2005; 54: 11-29.
16. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004; 5: 292-302.
17. Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol Rev 2004; 202: 275-293.
18. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411: 380-384.
19. Kershaw MH, Teng MW, Smyth MJ, Darcy PK. Supernatural T cells: genetic modification of T cells for cancer therapy. Nat Rev Immunol 2005; 5: 928-940.
20. Ho WY, Blattman JN, Dossett ML, Yee C, Greenberg PD. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 2003; 3: 431-437.
21. Rossig C, Brenner MK. Genetic modification of T lymphocytes for adoptive immunotherapy. Mol Ther 2004; 10: 5-18.
22. Mansoor W, Gilham DE, Thistlethwaite FC, Hawkins RE. Engineering T cells for cancer therapy. Br J Cancer 2005; 93: 1085-1091.
23. Gade TP, Hassen W, Santos E, Gunset G, Saudemont A, Gong MC et al. Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res 2005; 65: 9080-9088.
24. Pinthus JH, Waks T, Malina V, Kaufman-Francis K, Harmelin A, Aizenberg I et al. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J Clin Invest 2004; 114: 1774-1781.
25. Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res 2004; 64: 9160-9166.
26. Ma Q, Safar M, Holmes E, Wang Y, Boynton AL, Junghans RP. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy. Prostate 2004; 61: 12-25.
27. Rossig C, Bollard CM, Nuchtern JG, Rooney CM, Brenner MK. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood 2002; 99: 2009-2016.
28. Heemskerk MH, Hoogeboom M, Hagedoorn R, Kester MG, Willemze R, Falkenburg JH. Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J Exp Med 2004; 199: 885-894.
29. Cooper LJ, Al-Kadhimi Z, Serrano LM, Pfeiffer T, Olivares S, Castro A et al. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood 2005; 105: 1622-1631.
30. Guest RD, Hawkins RE, Kirillova N, Cheadle E J, Arnold J, O'Neill A et al. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother 2005; 28: 203-211.
31. Patel SD, Moskalenko M, Smith D, Maske B, Finer MH, McArthur JG. Impact of chimeric immune receptor extracellular protein domains on T cell function. Gene Ther 1999; 6: 412-419.
32. Moritz D, Groner B. A spacer region between the single chain antibody- and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity. Gene Ther 1995; 2: 539-546.
33. Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 2005; 115: 1616-1626.